Skip to main content

Table 3 Subgroup analysis of MTHFR polymorphisms rs1801133 and rs1801131

From: A meta-analysis on the susceptibility to the development of bladder cancer in the presence of DNMT3A, DNMT3B, and MTHFR gene polymorphisms

SNPs Genetic model Group Number of studies Asso P-val OR 95% CI
Rs1801133   Geographic region    
  T vs. C Western Asia 1 0.016 2.36 [1.168–4.779]
  TT vs. TC + CC North African 3 0.013 0.52 [0.311–0.872]
  TT + TC vs. CC South America 1 0.046 0.56 [0.320–0.990]
   Western Asia 1 0.036 2.38 [1.055–5.400]
   South America 1 0.033 0.556 [0.323–0.956]
  TT vs. TC North African 3 0.003 0.448 [0.261–0.769]
  TC vs. CC South America 1 0.026 0.506 [0.277–0.923]
   Genotyping methods    
  TC vs. CC PCR–RFLP 12 0.040 1.12 [1.005–1.269]
Rs1801131   Geographic region:    
  CC + CA vs. AA North African 1 0.047 1.68 [1.006–2.832]
  CC vs. CA North American 3 0.039 0.71 [0.523–0.984]
  CA vs. AA North African 1 0.025 1.86 [1.079–3.210]
   Genotyping methods    
  C vs. A PCR-Sequencing 1 0.004 0.69 [0.537–0.892]
  CC vs. CA + AA Taqman SNP genotyping assays 1 0.027 0.48 [0.250–0.920]
  CC + CA vs. AA PCR-Sequencing 1 0.003 0.53 [0.347–0.815]
  CC vs. AA PCR-Sequencing 1 0.003 0.45 [0.269–0.777]
  CC vs. CA Taqman SNP genotyping assays 1 0.011 0.419 [0.213–0.824]
  CA vs. AA PCR-Sequencing 1 0.013 0.56 [0.364–0.890]
  1. The bolds pointed to models that had statistically significant associations with BC